Correlation Between Adaptimmune Therapeutics and Inozyme Pharma

Can any of the company-specific risk be diversified away by investing in both Adaptimmune Therapeutics and Inozyme Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptimmune Therapeutics and Inozyme Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Adaptimmune Therapeutics Plc and Inozyme Pharma, you can compare the effects of market volatilities on Adaptimmune Therapeutics and Inozyme Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptimmune Therapeutics with a short position of Inozyme Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptimmune Therapeutics and Inozyme Pharma.

Diversification Opportunities for Adaptimmune Therapeutics and Inozyme Pharma

0.39

Correlation Coefficient

Adaptimmune Therapeutics  Inozyme Pharma

Weak diversification

The 3 months correlation between Adaptimmune and Inozyme is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Adaptimmune Therapeutics Plc and Inozyme Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inozyme Pharma and Adaptimmune Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptimmune Therapeutics Plc are associated (or correlated) with Inozyme Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inozyme Pharma has no effect on the direction of Adaptimmune Therapeutics i.e., Adaptimmune Therapeutics and Inozyme Pharma go up and down completely randomly.

Pair Corralation between Adaptimmune Therapeutics and Inozyme Pharma

Given the investment horizon of 90 days Adaptimmune Therapeutics is expected to generate 9.25 times less return on investment than Inozyme Pharma. In addition to that, Adaptimmune Therapeutics is 1.06 times more volatile than Inozyme Pharma. It trades about 0.01 of its total potential returns per unit of risk. Inozyme Pharma is currently generating about 0.07 per unit of volatility. If you would invest  176.00  in Inozyme Pharma on July 21, 2024 and sell it today you would earn a total of  378.00  from holding Inozyme Pharma or generate 214.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Adaptimmune Therapeutics Plc  vs.  Inozyme Pharma

Adaptimmune Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in November 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Inozyme Pharma

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Inozyme Pharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Inozyme Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Adaptimmune Therapeutics and Inozyme Pharma

The main advantage of trading using opposite Adaptimmune Therapeutics and Inozyme Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptimmune Therapeutics position performs unexpectedly, Inozyme Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inozyme Pharma will offset losses from the drop in Inozyme Pharma's long position.

The idea behind Adaptimmune Therapeutics Plc and Inozyme Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.